Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients
- 1 February 2002
- journal article
- Published by Elsevier in Kidney International
- Vol. 61 (2) , 609-614
- https://doi.org/10.1046/j.1523-1755.2002.00144.x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal diseaseAmerican Journal of Kidney Diseases, 1999
- Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patientsKidney International, 1999
- Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start?American Journal of Kidney Diseases, 1998
- Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patientsKidney International, 1997
- Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-Stage Renal Disease and Is Closely Linked to Plasma Folate and Pyridoxine ConcentrationsCirculation, 1996
- Membrane protein damage and methylation reactions in chronic renal failureKidney International, 1996
- Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsAtherosclerosis, 1996
- Net uptake of plasma homocysteine by the rat kidney in vivoAtherosclerosis, 1995
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995
- Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine‐homocysteine mixed disulphideEuropean Journal of Clinical Investigation, 1979